IUPAC: 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one · C₂₃H₂₇FN₄O₂ · MW 410.49 g/mol · CAS 106266-06-2
Risperidone (Risperdal, Perseris, Risperdal Consta). Second-generation "atypical" antipsychotic · serotonin–dopamine antagonist (SDA) · benzisoxazole derivative from Janssen, approved 1993. Used in schizophrenia, bipolar mania, and irritability in autism. Carries an FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis.
Risperidone is a serotonin–dopamine antagonist (SDA). Unlike the psychedelics that activate 5-HT2A, risperidone is a high-affinity competitive antagonist / inverse agonist that silences the receptor. Its defining feature is that it blocks 5-HT2A even more tightly than dopamine D2 — Ki ≈ 0.2 nM at 5-HT2A versus ≈ 3–4 nM at D2, roughly a 10–15-fold serotonin-over-dopamine preference. That ratio, not any single affinity, is what makes an antipsychotic "atypical" in the Meltzer framework (5-HT2A pKi − D2 pKi ≳ 1.2).
Blockade of postsynaptic D2 receptors in the mesolimbic pathway dampens hyperdopaminergic signaling, resolving positive symptoms (hallucinations, delusions). ~65–80% striatal D2 occupancy is the therapeutic window; above ~80% EPS emerge.
5-HT2A blockade disinhibits dopamine release in the nigrostriatal and mesocortical tracts. This locally counteracts D2 blockade in the striatum — buffering EPS at low dose — and lifts frontal DA, helping negative/cognitive symptoms.
Risperidone's 5-HT2A:D2 Ki ratio (~1:15) places it firmly in the atypical class. But the buffer is saturable: once 5-HT2A is fully occupied, extra dose only adds raw D2 blockade.
Potent α1 antagonism (Ki ~2–3 nM) drives orthostatic hypotension, reflex tachycardia, and sedation, especially on titration. α2 blockade (~4 nM) may add a modest noradrenergic/antidepressant nudge.
Moderate H1 antagonism (Ki ~20 nM) produces sedation and contributes to weight gain / appetite drive — though less than olanzapine or quetiapine. Muscarinic affinity is low, so anticholinergic load is minimal.
Unlike clozapine/quetiapine (fast-dissociating), risperidone binds D2 tightly and dissociates slowly. This is why, despite atypical status, it behaves like a "tight-binder" — high potency for hyperprolactinemia and dose-dependent EPS.
The four dopaminergic tracts respond differently to the same molecule. That divergence — therapeutic in one pathway, an adverse effect in another — is the entire story of antipsychotic pharmacology.
Risperidone is well absorbed orally (bioavailability ~70%, unaffected by food). Its pharmacology is inseparable from its major active metabolite: CYP2D6 hydroxylates it at the 9-position to 9-hydroxyrisperidone = paliperidone, which is itself an approved antipsychotic (Invega) and is essentially equipotent at D2/5-HT2A. Clinicians therefore dose to the combined "active antipsychotic moiety" (risperidone + paliperidone), which has a half-life of roughly 20 hours regardless of CYP2D6 phenotype.
Metabolism cascade: the dominant route is CYP2D6-mediated 9-hydroxylation to an active metabolite; a minor N-dealkylation route is inactive.
Paliperidone (9-OH-risperidone, marked ★) is the pharmacologically active metabolite and the reason CYP2D6 phenotype matters less for total effect than one might expect: poor metabolizers (~7–10% of Europeans, and patients on strong CYP2D6 inhibitors — paroxetine, fluoxetine, bupropion) accumulate more parent drug and less paliperidone, but the summed active-moiety exposure stays broadly similar. Strong 2D6 inhibition still shifts the balance and can raise total exposure enough to worsen dose-dependent side effects. CYP3A4 inducers (carbamazepine, rifampin, St John's Wort) can lower active-moiety levels and blunt efficacy.
The long-acting injectables exploit this PK: Risperdal Consta (microspheres, every 2 weeks) and paliperidone palmitate depots convert the ~20 h moiety into a months-long release, trading titration flexibility for adherence.
Risperidone's clinical personality changes with dose. At 2–4 mg/day it is a clean atypical: 5-HT2A is saturated, buffering the striatum, EPS are uncommon. Push past 6 mg/day and striatal D2 occupancy climbs above the ~80% EPS threshold while the 5-HT2A buffer — already maxed out — cannot compensate further. The drug then behaves more like a typical (first-generation) antipsychotic. This is the single most important dosing principle for risperidone.
D2 blockade in the ventral striatum/nucleus accumbens normalizes the aberrant dopamine signaling that drives positive symptoms — hallucinations, delusions, thought disorder. This is the intended target and is achieved across the therapeutic dose range. Onset of full antipsychotic effect takes days to weeks despite immediate receptor occupancy.
The dorsal striatum controls movement. At low dose, 5-HT2A antagonism disinhibits local dopamine and protects against extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism). Above ~6 mg/day the buffer is exhausted and D2 occupancy passes ~80% — EPS and, with chronic exposure, tardive dyskinesia become dose-limiting. Risperidone is the most EPS-prone of the common atypicals.
Dopamine from the arcuate nucleus tonically inhibits prolactin release. The pituitary sits largely outside the blood–brain barrier, so risperidone (and paliperidone) block those lactotroph D2 receptors with full peripheral force. Result: risperidone causes the most pronounced hyperprolactinemia of any atypical — often exceeding haloperidol — driving galactorrhea, amenorrhea, gynecomastia, sexual dysfunction, and, long-term, reduced bone density.
Hypodopaminergia in the prefrontal cortex is linked to negative symptoms (flat affect, avolition) and cognitive deficits. 5-HT2A antagonism disinhibits cortical dopamine release, offering modest benefit here — the theoretical advantage of atypicals over typicals. In practice the effect is real but limited, and best preserved by keeping the dose in the atypical window.
Approved uses: schizophrenia (adults and adolescents), bipolar I mania (mono- or adjunctive therapy), and irritability associated with autism in children — one of the few antipsychotics with a pediatric autism indication, where hyperprolactinemia and metabolic monitoring are especially important in a developing patient.
Evidence-based, non-moralistic. Risperidone is a prescription medication; most risk is dose-dependent and manageable with the lowest effective dose plus metabolic, prolactin, and movement monitoring. Never stop antipsychotics abruptly without a plan.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
5-HT2A
Serotonin 2A receptor (HTR2A)
|
Ki ≈ 0.2 nM
range 0.1–1 nM
|
Antagonist | |
|
D2
Dopamine D2 receptor (DRD2)
|
Ki ≈ 3.3 nM
range 0.4–10 nM
|
Antagonist | |
|
α1A
Alpha-1A adrenergic receptor
|
Ki ≈ 2.8 nM
range 2.3–10 nM
|
Antagonist | |
|
α2A
Alpha-2A adrenergic receptor
|
Ki ≈ 3.6 nM
range 3.6–28 nM
|
Antagonist | |
|
H1
Histamine H1 receptor
|
Ki ≈ 19 nM
range 2.6–100 nM
|
Antagonist |